Brett Monia, Ionis CEO

Up­dat­ed: Roche, Io­n­is launch new Hunt­ing­ton’s dis­ease study

SAN FRAN­CIS­CO — A new study for the Hunt­ing­ton’s dis­ease drug tomin­ersen, de­vel­oped in tan­dem by Roche and Io­n­is, “is open and has start­ed screen­ing el­i­gi­ble pa­tients,” a Roche spokesper­son told End­points News on Wednes­day. The Phase II tri­al will ex­am­ine whether tomin­ersen can slow the pro­gres­sion of Hunt­ing­ton’s in pa­tients aged 25 to 50 with very ear­ly or sub­tle signs of the dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.